Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG

References

• Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(32), 5078–5081 (2007).
   PubMed Web of Science ®Google Scholar
• Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J. Clin. Oncol.25(32), 5082–5086 (2007).
   PubMed Web of Science ®Google Scholar
• Bruner DW. Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model. J. Natl Cancer Inst. Monogr.37, 12–15 (2007).
   Google Scholar
• Buchanan DR, O’Mara AM, Kelaghan JW, Minasian LM. Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program. J. Clin. Oncol.23(3), 591–598 (2005).
   PubMed Web of Science ®Google Scholar
• Sloan JA, Frost MH, Berzon R et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer14, 988–998 (2006).
   PubMed Web of Science ®Google Scholar
• Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer41(2), 280–287 (2005).
   PubMed Web of Science ®Google Scholar
• Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual. Life Res.1(3), 211–218 (1992).
   PubMedGoogle Scholar
• Moinpour CV, Donaldson GW, Redman MW. Do general dimensions of quality of life add clinical value to symptom data? J. Natl Cancer Inst. Monogr.37, 31–38 (2007).
   Google Scholar
• Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st Century. Washington: National Academy Press (2001).
   Google Scholar
• Oliver A, Greenberg CC. Measuring outcomes in oncology treatment: the importance of patient-centered outcomes. Surg. Clin. N. Am.89(1), 17–25 (2009).
   PubMed Web of Science ®Google Scholar
• Avery KNL, Gurjal S, Blazeby JM. Patient-reported outcomes to evaluate surgery. Expert Rev. Pharmacoeconomics Outcomes Res.8(1), 43–50 (2008).
   PubMedGoogle Scholar
• Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J. Clin.57(5), 278–300 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Sprangers MAG. An introduction to quality of life assessment in oncology: the value of measuring patient-reported outcomes. Am. J. Manag. Care8(18 Suppl.), S550–S559 (2002).
   Google Scholar
• Krause NM, Jay GM. What do global self-rated health items measure? Medical Care32(9), 930–942 (1994).
   PubMed Web of Science ®Google Scholar
• Warnecke RB, Ferrans CE, Johnson TP et al. Measuring quality of life in culturally diverse populations. J. Natl Cancer Inst. Mongr.20, 29–38 (1996).
   Google Scholar
• Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision-making. Ann. Oncol.18(4), 775–781 (2007).
   PubMed Web of Science ®Google Scholar
• Efficace F, Bottomley A, Osoba D et al. Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials – does HRQOL evaluation in prostate cancer research inform clinical decision-making? J. Clin. Oncol.21(18), 3502–3511 (2003).
   PubMed Web of Science ®Google Scholar
• Au HJ, Brundage M, Ringash J et al. Added value of health-related quality of life (QoL) outcomes in NCIC CTG clinical trials: results from QoL Committee Workshop. Qual. Life Res. Suppl.A-71 (2007).
   Google Scholar
• Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain1(3), 277–299 (1975).
   PubMed Web of Science ®Google Scholar
• Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol.14(6), 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst.85, 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Osoba D, Tannock IF, Ernst D, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prenisone. J. Clin. Oncol.17(6), 1654–1663 (1999).
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.357(20), 2040–2048 (2007).
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Au HJ, Karapetis CS, O’Callaghan CJ et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J. Clin. Oncol.27(11), 1822–1828 (2009).
   PubMed Web of Science ®Google Scholar
• Shepherd F, Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur. J. Cancer30A, 635–642 (1994).
   PubMed Web of Science ®Google Scholar
• Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erolotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J. Clin. Oncol.24(24), 3831–3837 (2006).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Osoba D, Aaronson NK, Muller M et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual. Life Res.5(1), 139–150 (1996).
   PubMed Web of Science ®Google Scholar
• Taphoorn MJB, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol.6(12), 937–944 (2005).
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomized trial. Lancet359(9325), 2235–2241 (2002).
   PubMed Web of Science ®Google Scholar
• Davis AM, O’Sullivan B, Bell RS et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J. Clin. Oncol.20(22), 4472–4477 (2002).
   PubMed Web of Science ®Google Scholar
• Davis AM, Wright JG, Williams JI, Bombardier C, Griffin A, Bell RS. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual. Life Res.5(5), 508–516 (1996).
   PubMed Web of Science ®Google Scholar
• Davis AM, O’Sullivan B, Turcotte R et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol.75(1), 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood107(2), 431–434 (2006).
   PubMed Web of Science ®Google Scholar
• Norris B, Pritchard K, James K et al. A Phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/recurrent breast cancer (MBC): a National Cancer Institute of Canada (NCIC CTG) study. Proc. Am. Soc. Clin. Oncol.15, 98a (1996) (Abstract 59).
   Google Scholar
• Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J. Clin. Oncol.18(12), 2395–2405 (2000).
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N. Engl. J. Med.352(25), 2589–2597 (2005).
   PubMed Web of Science ®Google Scholar
• Bezjak A, Lee CW, Ding K et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J. Clin. Oncol.26(31), 5052–5059 (2008).
   PubMed Web of Science ®Google Scholar
• Jang RW, Le Maître A, Ding K et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J. Clin. Oncol.27(26), 4268–4273 (2009).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med.349, 1793–1802 (2003).
   PubMed Web of Science ®Google Scholar
• Ware JE, Snow KK, Kosinksi M et al. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, MA, USA (1993).
   Google Scholar
• Hilditch JR, Lewis J, Peter A et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas24, 161–175 (1996).
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J. Clin. Oncol.23(28), 6931–6940 (2005).
   PubMed Web of Science ®Google Scholar
• Savage C, Pater J, Tu D, Norris B. He said/she said: how much agreement is there on symptoms between common toxicity criteria and quality of life? Proc. Am. Soc. Clin. Oncol.21(Part 1), 386a (2002).
   Google Scholar
• Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced ovarian cancer. J. Natl Cancer Inst.92(9), 699–708 (2000).
   PubMed Web of Science ®Google Scholar
• Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J. Clin. Oncol.22(12), 2461–2468 (2004).
   PubMed Web of Science ®Google Scholar
• Duncan GG, Epstein JB, Tu D et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck27(5), 421–428 (2005).
   PubMed Web of Science ®Google Scholar
• Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol.108(1), 100–105 (2008).
   PubMed Web of Science ®Google Scholar
• Latreille J, Stewart D, Laberge F et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer3(5), 307–312 (1995).
   PubMed Web of Science ®Google Scholar
• Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a Phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.12(5), 1050–1057 (1994).
   PubMed Web of Science ®Google Scholar
• Dancey J, Zee B, Osoba D et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual. Life Res.6(2), 151–158 (1997).
   PubMed Web of Science ®Google Scholar
• Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J. Clin. Oncol.26(8), 1355–1363 (2008).
   PubMed Web of Science ®Google Scholar
• Curran D, Giralt J,Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol.25(16), 2191–2197 (2007).
   PubMed Web of Science ®Google Scholar
• Quinten C, Coens C, Mauer M et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol.10, 865–871 (2009).
   PubMed Web of Science ®Google Scholar
• Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual. Life Outcomes7, 102 (2009).
   PubMed Web of Science ®Google Scholar
• Coates AS, Hurny C, Peterson HF et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer: International Breast Cancer Study Group. J. Clin. Oncol.18(22), 3768–3885 (2004).
   Google Scholar
• Efficace F, Therasse P, Piccart MJ et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J. Clin. Oncol.22(16), 3381–3388 (2004).
   PubMed Web of Science ®Google Scholar
• Tross S, Herndon J 2nd, Korzun A et al. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer: Cancer and Leukemia Group B. J. Natl Cancer Inst.88(10), 661–667 (1996).
   PubMedGoogle Scholar
• Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J. Clin. Oncol.15(8), 2966–2973 (1997).
   PubMed Web of Science ®Google Scholar
• Pater J, Osoba D, Zee B. Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual. Life Res.7(3), 273–278 (1998).
   PubMed Web of Science ®Google Scholar
• Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – a systematic review to evaluate the added value in supporting clinical decision-making. Eur. J. Cancer44(11), 1497–1506 (2008).
   PubMed Web of Science ®Google Scholar
• Osoba D. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med. Care40(Suppl.), III-31–III-38 (2002).
   Web of Science ®Google Scholar
• Osoba D. The clinical value and meaning of health-related quality of life outcomes in oncology. In: Outcomes Assessment in Cancer: Measures, Methods, and Applications. Lipscomb J, Gotay CC, Snyder D (Eds). Cambridge University Press, UK, 386–405 (2005).
   Google Scholar
• Lipscomb J, Gotay CC, Snyder C. Introduction to outcomes assessment in cancer. In: Outcomes Assessment in Cancer: Measures, Methods, and Applications. Lipscomb J, Gotay CC, Snyder D (Eds). Cambridge University Press, UK, 1–14 (2005).
   Google Scholar
• Shih YCT, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J. Clin.58(4), 231–244 (2008).
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues, G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol.16, 139–144 (1998).
   PubMed Web of Science ®Google Scholar
• Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality-of-life assessment: patient compliance with questionnaire completion. J. Natl Cancer Inst.84(13), 1023–1026 (1992).
   PubMedGoogle Scholar
• Osoba D, Bezjak A, Brundage M, Pater J; National Cancer Institute of Canada Clinical Trials Group. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Value Health10(Suppl. 2), S138–S145 (2007).
   Google Scholar
• Bush N, Donaldson G, Moinpour C et al. Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. Qual. Life Res.14, 77–93 (2005).
   PubMed Web of Science ®Google Scholar
• Fayers P. Applying item response theory and computer adaptive testing: the challenges for health outcomes assessment. Qual. Life Res.16, 187–194 (2007).
   PubMed Web of Science ®Google Scholar
• Osoba D. Translating the science of patient-reported outcomes assessment into clinical practice. J. Natl Cancer Inst. Monogr.37, 5–11 (2007).
   Google Scholar
• Clauser SB, Ganz PA, Lipscomb J, Reeve BB. Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision-making. J. Clin. Oncol.25(32), 5049–5050 (2007).
   PubMed Web of Science ®Google Scholar
• Cella D, Yount S, Rothrock N et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap Cooperative Group during its first two years. Medical Care45(5), S3–S11 (2007).
   PubMed Web of Science ®Google Scholar
• Revicki DA, Sloan J. Practical and philosophical issues surrounding a national item bank: if we build it will they come? Qual. Life Res.16, 167–174 (2007).
   PubMed Web of Science ®Google Scholar
• Arora NK. Importance of patient-centred care in enhancing patient well-being: a cancer survivor’s perspective. Qual. Life Res.18, 1–4 (2009).
   PubMed Web of Science ®Google Scholar
• Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? Qual. Life Res.18, 115–123 (2009).
   PubMed Web of Science ®Google Scholar
• Lohr KN, Zebrack BJ. Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual. Life Res.18, 99–107 (2009).
   PubMed Web of Science ®Google Scholar
• Mandrekar S, Dueck A. Future direction in QOL research. Curr. Probl. Cancer.29(6), 343–351 (2005).
   PubMed Web of Science ®Google Scholar